

Cryptococcal Xylosyltransferase 1 (Cxt1p) from *Cryptococcus neoformans* Plays a Direct Role in the Synthesis of Capsule Polysaccharides^{*[S]}

Received for publication, October 30, 2007, and in revised form, March 14, 2008. Published, JBC Papers in Press, March 17, 2008, DOI 10.1074/jbc.M708927200

J. Stacey Klutts^{†S} and Tamara L. Doering^{†1}

From the Departments of [†]Molecular Microbiology and ^SPathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110

The opportunistic yeast *Cryptococcus neoformans* causes serious disease in humans and expresses a prominent polysaccharide capsule that is required for its virulence. Little is known about how this capsule is synthesized. We previously identified a β 1,2-xylosyltransferase (Cxt1p) with *in vitro* enzymatic activity appropriate for involvement in capsule synthesis. Here, we investigate *C. neoformans* strains in which the corresponding gene has been deleted (*cxt1Δ*). Loss of *CXT1* does not affect *in vitro* growth of the mutant cells or the general morphology of their capsules. However, NMR structural analysis of the two main capsule polysaccharides, glucuronoxylomannan (GXM) and galactoxylomannan (GalXM), showed that both were missing β 1,2-xylose residues. There was an ~30% reduction in the abundance of this residue in GXM in mutant compared with wild-type strains, and mutant GalXM was almost completely devoid of β 1,2-linked xylose. The GalXM from the mutant strain was also missing a β 1,3-linked xylose residue. Furthermore, deletion of *CXT1* led to attenuation of cryptococcal growth in a mouse model of infection, suggesting that the affected xylose residues are important for normal host-pathogen interactions. Cxt1p is the first glycosyltransferase with a defined role in *C. neoformans* capsule biosynthesis, and *cxt1Δ* is the only strain identified to date with structural alterations of the capsule polysaccharide GalXM.

Cryptococcus neoformans is an opportunistic fungal pathogen of humans and other mammals that causes serious disease, including infections of both the lung and central nervous system (1). Neurological infections with *C. neoformans* typically occur in immunocompromised patients and are often debilitating or fatal. Anti-cryptococcal therapies that are currently available can resolve symptoms in many cases, but these drugs

do not eradicate the organism from neural tissues (1). Recurrence is likely, and new therapies for this infection are needed.

The main virulence factor of *C. neoformans* is the carbohydrate capsule surrounding the cell. Strains of *C. neoformans* lacking this structure do not cause disease in animal models (2), suggesting that the mechanisms of capsule synthesis are potential drug targets (3). The capsule is composed of two polysaccharides, glucuronoxylomannan (GXM)² and galactoxylomannan (GalXM), and a small amount of mannoproteins (3).

The structures of both GXM and GalXM were resolved by Cherniak and colleagues (4, 5) a decade ago. GXM is a large polysaccharide (1–7 megadaltons) (6) composed of α 1,3-linked mannan with glucuronic acid and xylose side chains (4) (Fig. 1A). The mannose residues of GXM are also variably 6-O-acetylated (7). GalXM is a smaller polymer (~100 kDa), consisting of an α 1,6-galactan backbone with galactomannan side chains that are further substituted with variable numbers of xylose residues (5) (Fig. 1B).

GXM mediates diverse negative effects on the host immune response (8) and is well established as a critical virulence factor for *C. neoformans*. Our understanding of the importance of GalXM in virulence is not as complete, but recent studies suggest that it may play a role both in altering the immune response to *C. neoformans* (9) and in the virulence of this organism (10).

The synthetic pathways of the *C. neoformans* capsule polysaccharides, including the order in which the different sugar residues are added, have remained elusive. The structures of GXM and GalXM imply that a diverse set of glycosyltransferase enzymes will be needed to generate these polymers (3), but little is known about these fundamental catalysts of capsule synthesis. Recently, we reported the identification of a novel β 1,2-xylosyltransferase (Cxt1p) from *C. neoformans* that transfers xylose to α 1,3-linked dimannoside (11), an activity appropriate for the synthesis of both GXM and GalXM (see Fig. 1). Here, we report the generation of *CXT1* deletion strains (*cxt1Δ*) and characterization of these strains, including evaluation of capsule polysaccharide structures and assessment of virulence in a murine model. Cxt1p plays a primary role in GalXM synthesis and is also involved in GXM production; its deletion leads to attenuation of growth in a mouse model of infection. This is the first cryptococcal glycosyltransferase shown to have

^{*} This work was supported, in whole or in part, by National Institutes of Health Grants GM R01 071007 (to T. L. D.) and GM F32 072341 (to J. S. K.). This work was also supported by Department of Energy Center for Plant and Microbial Complex Carbohydrates Grant DE-FG09-93ER-20097 and a William Keck Foundation Postdoctoral Fellowship (to J. S. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[S] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Tables S1–S3 and Figs. S1–S3.

¹ To whom correspondence should be addressed: 660 South Euclid Ave., Campus Box 8230, St. Louis, MO, 63110-1093. Tel.: 314-747-5597; Fax: 314-362-1232; E-mail: doering@wustl.edu.

² The abbreviations used are: GXM, glucuronoxylomannan; GalXM, galactoxylomannan; NAT, nourseothricin acetyltransferase; MOPS, 4-morpholinepropanesulfonic acid; HSQC, heteronuclear single quantum coherence; XT, xylosyltransferase.

C. neoformans β 1,2-Xylosyltransferase




FIGURE 1. Repeating structures of GXM and GalXM from *C. neoformans*. *A*, the structure of serotype D GXM (4). Approximately 60% of the mannose residues are also 6-*O*-acetylated (7) (not shown). *B*, the structure of GalXM (5). Xyl, xylose; GlcA, glucuronic acid; Man, mannose; Gal, galactose.

a direct role in capsule biosynthesis, and the *cxt1* Δ mutant is the first *C. neoformans* strain with a demonstrated structural defect in GalXM.

EXPERIMENTAL PROCEDURES

Materials—Media components were from Difco, nourseothricin (ClonNat) was from Werner BioAgents (Germany), and oligonucleotides were from Integrated DNA Technologies. Reagents for DNA isolation and biolistic transformation were from Bio-Rad. DH5 α cells, TOPO TA[®] cloning kits, and some restriction enzymes were from Invitrogen; other restriction enzymes were from New England Biolabs. Kits for purification of DNA fragments and PCR products were from Qiagen. Unless noted, all other reagents were from Sigma.

Strains and Cell Growth—*C. neoformans* wild-type strains JEC20 and JEC21 (serotype D *MAT* **a** and α , respectively) were provided by Joseph Heitman (Duke University) and the CAP67 mutant strain (*MAT* α serotype D *cap59*) was provided by June Kwon-Chung (National Institutes of Health). Strains were grown in YPD medium (1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose) at 30 °C with continuous shaking (200 rpm) or on YPD agar plates. Growth at 30 and 37 °C was also assessed on YPD plates with and without 0.05% SDS.

Amplification and Cloning of *CXT1* into TOPO pCR2.1—The sequence of the *CXT1* gene (GenBank[™] accession number 3254907) and its flanking regions was obtained from the sequence of chromosome 12 (accession number AE017352) within the *C. neoformans* serotype D genomic sequence in the NCBI data base. Genomic DNA from JEC21 was isolated as previously described (12). This was used as the template for PCR amplification of *CXT1* and its flanking sequences using a sense PCR primer (CXT1S, TGGGGTCCATAAAATGTCGTT) corresponding to a region 1.3-kb upstream of the *CXT1* start codon and an antisense primer (CXT1A, CCGCAGAGTAGAGAAGGAGG) corresponding to 1 kb downstream of the gene. The 5-kb PCR product was cloned into the TOPO pCR2.1 vector according to the manufacturer's directions, and the resulting plasmid (TOPO-*CXT1*) was maintained in the DH5 α *Escherichia coli* strain.

***CXT1* Gene Disruption**—The genomic copy of *CXT1* was replaced with a nourseothricin acetyltransferase (NAT) (13)

resistance gene using a replacement cassette consisting of the NAT sequence flanked by the 5'- and 3'-untranslated regions of *CXT1* (Fig. 2). To generate this construct, the TOPO-*CXT1* vector was digested with BsmI and SspI to remove the *CXT1* open reading frame, and the ends of the cut plasmid were blunted using T4 DNA polymerase. The NAT gene was released from the GMC-200 plasmid (provided by Gary Cox, Duke University Medical Center) using HpaI and EcoRV and the resulting fragment was gel purified and blunt-end cloned between the BsmI and

SspI sites of TOPO-*CXT1*. Primers CXT1S and CXT1A (above) were then used to PCR amplify this region to generate linear DNA, which was used to biolistically transform the *C. neoformans* CAP67 strain as previously described (14). A separate replacement cassette was generated in the same manner, except the *CXT1* gene was excised from TOPO-*CXT1* with AvrII and SspI, removing only the 3' two-thirds of the gene. This was used to replace *CXT1* in a JEC21 background.

Screening of *CXT1* Gene Disruption Candidates by PCR and Confirmation by Southern Blot—Genomic DNA was extracted from drug-resistant transformants as previously described (15) and screened by PCR in the presence of 5% dimethyl sulfoxide (13) to confirm the absence of the *CXT1* gene and the presence of the NAT marker in its place (supplemental Fig. 1). Genomic DNA from WT, *cxt1* Δ , and isogenic wild-type strains derived from JEC21 was also digested with NcoI (which cuts within the *CXT1* coding sequence but not that of NAT) and blotted using standard techniques (16) with probes corresponding to *CXT1* and NAT. DNA blotting confirmed gene replacement and that the marker cassette was present only once in the genome, with no additional ectopic insertions (data not shown).

Strain Backcrosses—To obtain a *cxt1* Δ strain in an encapsulated strain background, the CAP67 *cxt1* Δ strain was crossed to JEC20 on V8 agar as described in Ref. 17, and the resulting spores were plated on solid medium containing nourseothricin. An encapsulated, nourseothricin-resistant, *MAT***a** strain from this cross was then backcrossed to JEC21 eight times with spore selection on nourseothricin plates. After the ninth cross, spores were plated onto YPD plates and an isogenic *MAT* α pair was obtained, differing only at the *CXT1* locus. To obtain an isogenic pair in the CAP67 background, an acapsular, nourseothricin-resistant, *MAT***a** colony from the first cross above was crossed three times to the CAP67 strain.

Crude Membrane Preparation and Xylosyltransferase Activity Analysis—Wild-type and *cxt1* Δ strains were grown in 50 ml of YPD medium and crude membranes were prepared as previously described (11). Xylosyltransferase activity of the membranes was assayed based on the transfer of [¹⁴C]xylose from UDP-[¹⁴C]Xyl to a Man- α 1,3-Man (Man₂) acceptor. The product was separated from unconsumed UDP-Xyl and detected by

scintillation counting and thin-layer chromatography, also as previously described (11).

Immunofluorescence—Wild-type and *cxt1* Δ strains were stained as in Ref. 18 with anti-GXM monoclonal antibodies 1255, F12D2, and 3C2 (from Tom Kozel, University of Nevada at Reno (19)) and an Alexa Fluor 546-tagged anti-mouse secondary antibody (Invitrogen). Samples were visualized on a Zeiss Axioskop2 MOT Plus microscope (Carl Zeiss) under phase-contrast and fluorescence-filtered conditions.

Purification of GXM—GXM was purified essentially as previously described (20). 500 ml of capsule induction medium (35 mM MOPS, pH 7.1, 12 mM NaHCO₃, 2% (w/v) dextrose, 1.5 g/liter asparagine, 1.7 g/liter yeast nitrogen base without amino acids and ammonium sulfate) was inoculated with the appropriate strains and incubated for 5 days at 30 °C. The cultures were next autoclaved and centrifuged at 18,000 \times g for 1 h at room temperature to pellet the cells. The supernatant was filtered with a 0.22- μ m membrane, adjusted to 0.2 M NaCl, and 15 g of hexadecyltrimethylammonium bromide were added to the solution with stirring. After dissolution, 1 liter of 0.05% hexadecyltrimethylammonium bromide was added slowly with stirring and the solution left at room temperature overnight to allow precipitation of GXM. The resulting mixture was subjected to centrifugation (18,000 \times g, 1 h, 4 °C), the supernatant fraction was discarded, and the pellet was suspended in 10% ethanol and re-centrifuged. The pellet was then dissolved in 200 ml of 2 M NaCl by stirring at room temperature overnight, and the GXM was precipitated by slowly adding \sim 600 ml of cold 95% ethanol and incubating for 6 h at 4 °C. The precipitate was recovered by centrifugation and the pellet was dissolved overnight in 150 ml of 2 M NaCl. The resulting solution was dialyzed (3,500 MWCO) against 4 liters of diH₂O for 5 days with daily water changes, frozen, and lyophilized to dryness.

Purification of GalXM—GalXM was purified based on the methods of Vaishnav *et al.* (5). 200 ml of YPD medium was inoculated with either CAP67 or CAP67 *cxt1* Δ and incubated at 30 °C with shaking for 5 days. Cells were sedimented (9000 \times g, 10 min) and the supernatant fraction was concentrated to \sim 10 ml with a Pall Jumbosep spin concentrator containing a 10-kDa MWCO membrane. After addition of 30 ml of buffer CA (10 mM Tris-HCl, pH 7.2, 0.5 M NaCl, 1 mM CaCl₂, 1 mM MnCl₂), the sample was re-concentrated to 10 ml, mixed with 20 ml of buffer CA, and filtered through a 0.22- μ m filter to remove any remaining cells or debris. The filtered sample was applied to a column containing 40 ml of concanavalin A resin (Type IV) that had been pre-equilibrated with buffer CA. The sample was re-circulated (\sim 20 ml/h) through the column for 18 h at 4 °C using a multichannel peristaltic pump, and the column was then eluted and washed with 200 ml of buffer CA, collecting all volume. The wash/eluate was dialyzed overnight against 4 liters of diH₂O, lyophilized to dryness, re-suspended in \sim 15 ml of buffer DW (10 mM Tris-HCl, pH 7.6), and concentrated to 1 ml. After four rounds of re-suspension and re-concentration to remove salt, the sample (\sim 15 ml) was applied to a column containing 230 ml of DE-52 anion exchange resin (Whatman) that had been equilibrated with buffer DW. The col-

umn was washed with 250 ml of the same buffer, discarding the flow-through, and eluted with a 1-liter linear gradient from buffer DW to buffer DE (10 mM Tris-HCl, pH 7.6, 1 M NaCl), collecting 10-ml fractions. 500 μ l of each fraction was assayed for carbohydrate using the phenol-sulfuric acid method (21). The first peak of carbohydrate eluting from the column was pooled, lyophilized, and re-suspended in buffer GF (10 mM Tris-HCl, pH 7.2, 100 mM NaCl). The sample was filtered and applied to a 316-ml HiPrep 26/60 Sephacryl S-300 gel filtration column (GE Healthcare) that was pre-equilibrated with Buffer GF. The column was eluted with a 253-ml (0.8 column volume) isocratic gradient of Buffer GF, with the first 95 ml (void volume) going to waste. The remaining 158 ml were collected into 4-ml fractions and assayed for carbohydrate as above. The single carbohydrate peak was pooled, dialyzed for 5 days against diH₂O, and lyophilized.

NMR Spectroscopy of GXM—GXM samples were dissolved in water (5 mg/ml) and sonicated to reduce the molecular weight. The samples were then deuterium exchanged by lyophilization from D₂O (99.9% D, Aldrich) and dissolved in 0.7 ml of D₂O (99.96% D, Cambridge Isotope Laboratories). Proton, gradient enhanced COSY (gCOSY), and HSQC NMR spectra were acquired on a Varian Inova-500 MHz spectrometer at 70 °C using standard Varian pulse sequences. Proton chemical shifts were measured relative to acetone ($\delta_{\text{H}} = 2.225$, $\delta_{\text{C}} = 31.07$ ppm), and xylose H-1 peak volumes were measured by integration of the HSQC spectra. Samples were also deacetylated by adjusting to pH 11 with concentrated NH₄OH, followed by incubation at 25 °C for 24 h, dialysis, and lyophilization. The acetylated samples were again deuterium exchanged and dissolved in 0.7 ml of D₂O. TOCSY, gCOSY, HSQC, and NOESY spectra were recorded at 70 °C. TOCSY and NOESY mixing times were 60 and 250 ms, respectively. ¹H and ¹³C NMR assignments for GXM are described in supplementary data Table S1.

NMR Spectroscopy of GalXM—GalXM samples were deuterium-exchanged by lyophilization from D₂O and dissolved in 0.7 ml of D₂O. Proton, gCOSY, TOCSY, NOESY, and HSQC NMR spectra were acquired on Varian Inova-500 MHz and 600 MHz spectrometers at 70 °C. TOCSY and NOESY mixing times were 100 and 300 ms, respectively. ¹H and ¹³C NMR assignments for GalXM are indicated in supplementary data Tables S2 and S3.

Glycosyl Linkage Analysis of GalXM—GalXM samples were permethylated, depolymerized, reduced, and acetylated; the resulting partially methylated alditol acetates were then analyzed by gas chromatography-mass spectrometry as described by York and colleagues (22). Briefly, an aliquot of each sample was suspended in 200 μ l of dimethyl sulfoxide and stirred for 2 days before permethylation by the method of Ciucanu and Kerek (23). Following permethylation, this material was hydrolyzed with 2 M trifluoroacetic acid (2 h in a sealed tube at 121 °C), reduced with NaBD₄, and acetylated using acetic anhydride/trifluoroacetic acid. The resulting partially methylated alditol acetates were analyzed on a Hewlett Packard 5890 GC interfaced to a 5970 MSD (mass selective detector, electron impact ionization mode); sep-

C. neoformans β 1,2-Xylosyltransferase




FIGURE 2. **Generation of *CXT1* deletion strains.** Shown are the *CXT1* deletion construct (above) and corresponding genomic region (below) with lengths of homologous targeting sequences (gray) indicated.

ration was performed on a 30M Supelco 2330 bonded phase fused silica capillary column.

In Vivo Growth in Mice—For each strain of *C. neoformans* tested, eight 4–6-week-old C57Bl/6 female mice were anesthetized with ketamine and intranasally inoculated with 2 to 5×10^4 cryptococcal cells in $50 \mu\text{l}$ of saline as in Refs. 24 and 25. Three mice were sacrificed at 1 h post-inoculation and the remaining 5 were sacrificed after 1 week. After sacrifice, the lungs were harvested and serial dilutions were plated on YPD agar to quantitate colony forming units.

RESULTS

Generation of *CXT1* Deletion Strains—To begin defining the role in cryptococcal biology and capsule synthesis of the β 1,2-xylosyltransferase we discovered (10), we deleted the corresponding gene (*CXT1*) in the acapsular *C. neoformans* strain CAP67. This strain lacks GXM and has therefore been the primary source for isolation of the less abundant capsule polysaccharide, GalXM (5). We first made a construct containing the nourseothricin drug resistance marker (NAT) flanked by the *CXT1* 5'- and 3'-untranslated regions (Fig. 2). After biolistic transformation, nourseothricin-resistant colonies were screened by PCR for the desired gene replacement (supplemental Fig. S1). A correct transformant was identified and genetic crossing was used to obtain *cxt1* Δ and *CXT1* isogenic pairs in both encapsulated and acapsular strain backgrounds (see “Experimental Procedures”). Gene replacement and single site insertion was confirmed in these strains by DNA blotting (data not shown).

Xylosyltransferase (XT) Activity in *cxt1* Δ Strains—To confirm that deletion of *CXT1* led to loss of XT activity, membranes from the isogenic *cxt1* Δ /*CXT1* pairs were assayed as previously described (11). In this assay wild-type membranes produce a dominant xylosylated product, Xyl- β 1,2-Man- α -1,3-Man (10), only in the presence of a Man- α 1,3-Man (Man_2) substrate (Fig. 3, first two tracks). This activity was dramatically reduced by deletion of *CXT1* in both encapsulated and acapsular strain backgrounds (Fig. 3 and data not shown). In some experiments, we did observe minor residual XT activity in *cxt1* Δ membranes; this formed a product that co-migrated with the wild-type product on TLC plates (data not shown; see “Discussion”).

Growth and Capsule Morphology of *cxt1* Δ —We assessed growth of the encapsulated *cxt1* Δ strain relative to its isogenic wild-type partner and JEC21. Growth at 30 and 37 °C on YPD agar with and without SDS and in YPD medium at 30 °C was comparable for all strains (data not shown). The mutation therefore does not alter overall viability in standard culture conditions.




FIGURE 3. **Xylosyltransferase activity in encapsulated *cxt1* Δ and wild-type strains derived from JEC21.** A standard XT assay of membranes from the indicated strains, incubated without (–) or with (+) the Man- α 1,3-Man (Man_2) substrate, was performed; an autoradiogram of a thin layer chromatograph of the products is shown. Migration positions of xylose (Xyl) and Man_2 standards are indicated. *CXT1*, isogenic wild-type strain; O, origin; arrow, direction of migration.

We also examined capsule morphology of Δ *cxt1* and wild-type cells. Cells grown in liquid culture were well separated and excluded India Ink from a region around the cell, both suggesting the presence of capsular material (data not shown). As another approach to detecting potentially subtle capsule alterations, we examined capsule binding with a panel of anticapsular monoclonal antibodies, including two that are thought to require capsular xylose for binding (19). In these experiments, the *cxt1* Δ strain stained similarly to its isogenic wild-type partner and JEC21 with all antibodies tested (data not shown). This suggested that any capsule defect in the mutant was less drastic than complete loss of xylose.

Analysis of Capsule Polysaccharides—The definitive means of establishing the role of an enzyme in capsule polysaccharide synthesis is structural analysis. We therefore purified GXM and GalXM and analyzed these polymers for defects that could not be detected by microscopy or immunofluorescence. GXM was purified from the encapsulated *cxt1* Δ and the wild-type pair as previously described (20). The results of the NMR analysis of the GXM samples are shown in Table 1. Notably, there was an \sim 30% decrease in the amount of xylose in GXM, confirmed by one- or two-dimensional NMR in both native and deacetylated GXM. HSQC analysis of the deacetylated GXM allowed resolution of specific mannose residues. Comparing the mutant to wild-type, there is a decrease of 39% in the anomeric proton signal from the mannose substituted on O-2 with xylose (ManX-2) and a 31.5% increase in the amount of signal from O-2-unsubstituted mannose (Man-2). These changes also support the loss of roughly one-third of the β 1,2-linked xylose (see Fig. 1A). Two additional minor xylose residues detected (Xyl-A-1 and Xyl-B-1) were also reduced in the mutant strain. In contrast, there was little change in the abundance of glucuronic

TABLE 1
Integration results of NMR spectra from GXM analysis

Sample	Method	Residue ^{a,b}	CXT1	<i>cxt1</i> Δ	% Difference	Average Xyl % difference
GXM	HSQC (two-dimensional)	GlcA-1	61.0	57.4	-5.9	
		Xyl-1	60.7	42.1	-30.6	
		GlcA-4	83.2	76.8	-7.7	
		Xyl-4	147.7	98.7	-33.2	
		GlcA-5	101.2	104.3	3.1	
		GlcA-3 + Xyl-3	233.8	175.6	-24.9	
		GlcA-2 + Xyl-2	306.2	247.6	-19.2	
		Xyl-5a	117.2	71.2	-39.2	
		Man-1	100.0	100.0	0	
Deacetylated GXM	One-dimensional proton	Man	100.0	100.0	0	
		Xyl	40.4	28.3	-29.9	
						-29.9
	HSQC (two-dimensional)	Man-1	100.0	100.0	0	
		ManX-2	32.5	19.8	-39.1	
		ManG-2	32.9	32.5	-1.3	
		Man-2	34.9	50.9	31.5	
		Xyl-1	34.7	26.6	-23.5	
		Xyl-5a	35.9	25.3	-29.6	
		Xyl-5e	26.0	14.6	-43.8	
		Xyl-A-1	7.6	4.2	-44.7	
		Xyl-B-1	9.3	7.9	-14.9	
		GlcA-5	52.8	52.2	-1.1	
		GlcA-1	39.8	43.0	7.4	

^a GlcA = glucuronic acid; Xyl = xylose; Man = mannose.^b Numbers represent the carbon number with which the proton is associated; a = axial, e = equatorial.**TABLE 2**
HSQC integration results of GalXM

Residue	CXT1		<i>cxt1</i> Δ	
	Volume	Normalized volume ^a	Volume	Normalized volume ^a
4- β -Galp	0.37	0.51	0.52	0.63
3,4- β -Galp	0.36	0.49	0.30 ^b	0.37 ^b
α -Manp	0.2	0.27	0.71	0.87
3- α -Manp-(1 \rightarrow 3M)	0.33	0.45	ND ^c	
3- α -Manp-(1 \rightarrow 4G)	ND		0.59	0.72
2,3- α -Manp	0.55	0.75	0.25 ^d	0.3 ^d
β -Xylp-(1 \rightarrow 3G)	0.25	0.34	0.30 ^b	0.37 ^b
β -Xylp-(1 \rightarrow 3M)	0.54	0.74	n.d./0.09 ^{e,e}	-/0.11 ^e
β -Xylp-(1 \rightarrow 2M)	0.76	1.04	0.09/ND ^{e,e}	0.11/- ^e

^a Based on 4- β -Galp + 3,4- β -Galp = 1.^b 3,4- β -Galp and β -Xylp-(1 \rightarrow 3G) overlapped in *cxt1* Δ . Because these should be equimolar (Fig. 1B), the individual volumes were obtained by dividing the sum by 2.^c ND, not detected.^d The 2,3- α -Manp peak overlaps with two other peaks in the proton dimension, thus the volume for this residue is an estimated value.^e One of these residues was not detected, whereas the other was drastically reduced. However, overlap of the low intensity signals from these residues makes it impossible to resolve which is missing (see text).

acid or of the mannose residues to which glucuronic acid was attached.

We purified GalXM from culture supernatants of the acapsular *cxt1* Δ and isogenic wild-type strains as described under "Experimental Procedures." Table 2 shows the integration of peaks corresponding to residues of GalXM in two-dimensional (HSQC) NMR analysis. The structure of GalXM that was derived from NMR analysis of the wild-type strain was identical to that previously published (5) (Fig. 1B) (data not shown). Analysis of *cxt1* Δ GalXM was complicated by overlap of low intensity signals, as indicated in the footnotes of Table 2. Despite this limitation, we observed almost complete loss of both β -xylose residues that are linked to mannose (Fig. 1B) in the *cxt1* Δ strain, whereas the amount of β -xylose linked to galactose (β -Xylp-(1 \rightarrow 3G)) was unchanged. Signals corresponding to a minor amount of mannose-linked xylose was

detected (Table 2), but due to the low abundance of this residue, we could not conclusively determine whether the residual xylose was linked β 1,2 or β 1,3.

To confirm the dramatic loss of xylose from GalXM, and to address the source of the residual xylose we detected, we performed linkage analysis of GalXM. The results of this study (Table 3 and supplemental Figs. S2 and S3) confirm a sharp decrease in both residues, with loss of the β -Xylp-(1 \rightarrow 2M) residue causing almost complete loss of 2,3-mannose and loss of the β -Xylp-(1 \rightarrow 3M) residue yielding a more than 3-fold increase in terminal mannose (t-Man) (Table 3 and Fig. 1B). Notably, the loss of these two distal xylose residues leads to opposite effects on 3-linked mannose (3-Man): 3-Man increases with loss of the 2-linked xylose and decreases with the loss of the 3-linked xylose (Fig. 1B). For this reason we were still unable to definitively resolve the source of the residual mannose-linked xylose in the mutant GalXM (see "Discussion").

No terminal xylose was detected in the mutant by linkage analysis (Table 3), even though 3,4-linked galactose was still present (corresponding to the presence of a terminal sugar linked β 1,3 to galactose; see Fig. 1B). Furthermore, terminal xylose was detected in the mutant by NMR, albeit drastically reduced compared with wild-type. The loss of xylose in the linkage analysis may be due to evaporation of permethylated xylose, which has a low boiling point. Low recovery of terminal xylose was also observed in the wild-type sample, where we detected only 12.4 mol % of terminal xylose (t-Xyl) despite detecting 35.4 mol % of the residues (2,3-Man, 3-Man, and 3,4-Gal) to which terminal xylose is linked (Table 3).

*Pulmonary Growth of Encapsulated *cxt1* Δ Strains in Mice*—To assess the impact of CXT1 on virulence, the encapsulated *cxt1* Δ , isogenic wild-type, and JEC21 strains were each inoculated intranasally into eight C57Bl/6 female mice as previ-

C. neoformans β 1,2-Xylosyltransferase

TABLE 3
Linkage analysis of GalXM

Residue ^{a,b}	<i>CXT1</i>		<i>cxt1</i> Δ	
	Area	Mol %	Area	Mol %
Terminal xylopyranosyl (t-Xyl)	17,173,422	12.4	ND ^c	
2,3-Linked mannopyranosyl (2,3-Man)	21,744,638	15.7	322,020	0.2
3-Linked mannopyranosyl (3-Man)	18,164,419	13.1	44,184,845	20.8
Terminal mannopyranosyl (t-Man)	7,206,471	5.2	39,962,848	18.8
6-Linked galactopyranosyl (6-Gal)	19,557,342	14.1	39,642,211	18.6
3,6-Linked galactopyranosyl (3,6-Gal)	21,175,731	15.3	36,949,899	17.4
4-Linked galactopyranosyl (4-Gal)	17,107,085	12.3	26,362,816	12.4
3,4-Linked galactopyranosyl (3,4-Gal)	9,145,202	6.6	13,039,498	6.1
Terminal gluco- or galactofuranosyl (t-Glcf/Galf)	4,925,987	3.6	5,903,251	2.8
Terminal galactopyranosyl (t-Gal)	1,276,231	0.9	2,147,622	1.0
3-Linked galactopyranosyl (3-Gal)	1,278,349	0.9	4,229,861	2.0
	138,754,877	100	212,422,851	100

^a GalXM residues in bold differ most drastically between the WT and mutant strains.

^b Residues that were <1.5 mol % ($n = 9$) in both strains and were inconsistent with the structure of GalXM were omitted from this table and calculations.

^c ND, not detected; see text.




FIGURE 4. Growth of cryptococcal strains in murine lungs is attenuated in the absence of *CXT1*. Growth of each strain indicated was assessed by comparing colony forming units in the lungs of mice at 1 h (open bars) and 7 days (black bars) post-inoculation. The mean \pm S.E. are plotted. All strains tested were derived from JEC21.

ously described (24, 25). As shown in Fig. 4, the number of colony forming units was similar at 1 h after inoculation for all three strains ($p > 0.5$). However, by 1 week post-inoculation, the number of colony forming units in the lungs of mice infected with the *cxt1* Δ strain was significantly reduced compared with either of the wild-type strains ($p = 0.013$ for the isogenic partner and $p = 0.002$ for JEC21). This shows that loss of *CXT1* leads to attenuation of virulence.³ A similar growth defect in mice was also observed in an encapsulated serotype D strain of *C. neoformans*, which did not express XT activity due to truncation of *CXT1* after nucleotide 917 (11) (data not shown).

DISCUSSION

The pathways involved in synthesis of *C. neoformans* capsule polysaccharides have proven difficult to elucidate, and to date no glycosyltransferases have been clearly implicated in this process (26). We previously discovered a cryptococcal xylosyltransferase (Cxt1p) that transfers xylose to α 1,3-dimannoside in a β 1,2-linkage (11). We have now demonstrated

that this transferase participates in synthesis of both GXM and GalXM.

We performed most of our studies using cells bearing a complete deletion of *CXT1*. Interestingly, we still detected a small amount (<5% of wild type; not shown) of the normal Cxt1p product in assays performed with membranes from these mutants. We speculate that this product is formed by a second XT enzyme whose similar activity is only detectable in the absence of the more robust *CXT1*-encoded enzyme.

Encapsulated strains lacking Cxt1p had normal capsule morphology at the level of light microscopy, and no apparent defect in binding of anticapsular monoclonal antibodies. This is not surprising, because these antibodies were generated against GXM (27–29), and the only defect in the structure of that polysaccharide in *cxt1* Δ cells is an approximate 30% reduction in β 1,2-linked xylose. The nature of the enzyme or enzymes responsible for incorporation of the remaining GXM xylose remains an outstanding question of capsule synthesis.

In contrast to the limited effects of Cxt1p loss on GXM structure, GalXM from the *cxt1* Δ mutant strain showed an almost complete lack of the two xylose residues linked to mannose (Fig. 1B). The loss of the xylose-linked β 1,2 to the reducing mannose of an α 1,3-linked dimannose segment is precisely consistent with the *in vitro* activity of Cxt1p (11). There are two possible explanations for the loss of the more distal β 1,3-linked xylose (Fig. 1B): either Cxt1p also has a β 1,3-XT activity (which we have not observed *in vitro*) or, more likely, a separate β 1,3-XT enzyme requires the presence of the β 1,2-linked xylose before utilizing GalXM as an acceptor. The latter interpretation would also indicate the order of addition of those two xylose residues.

Our analyses showed that a minor amount of mannose-linked xylose remains in GalXM purified from *cxt1* Δ cells. For technical reasons discussed above, we could not verify whether this xylose is linked β 1,2 or β 1,3. If this linkage is β 1,3, then it is possible that the β 1,3-XT can transfer a small amount of xylose even in the complete absence of the β 1,2 residue. If this linkage to mannose is β 1,2, one intriguing possibility is that its attachment is mediated by the second, less robust XT we detected in our analysis of *cxt1* Δ enzyme activity. Future studies of the second enzyme will explore this possibility.

³ As part of a large-scale gene deletion project (10), mutants in *CXT1* (termed CAP3 in that report) were tested in a different mouse model and showed no phenotypic change; this may be due to the different strain backgrounds, larger inoculum, or intravenous route of infection employed in that study.




FIGURE 5. Cryptococcal GalXM (left) and glycosylinositol phosphorylceramide (right) share a tetrasaccharide structural motif (boxed). Galactose, open circles; mannose, gray circles; xylose, open stars; IPC, inositol phosphoceramide.

In an interesting biological parallel, cryptococcal glycolipids have structural overlap with capsule polysaccharides. *C. neoformans* produces glycosylinositol phosphorylceramides; the most abundant of these contains a structural motif (Man α 1,3(Xyl β 1,2)Man α 1,4Gal) that resembles a segment of GalXM (30, 31) (see Fig. 5). Structural analysis of this glycosylinositol phosphorylceramide in the encapsulated *cxt1* Δ strain revealed complete loss of the β 1,2-linked xylose (32) indicating that Cxt1p plays a critical role in β 1,2-linked xylose addition to these compounds. Our data thus indicate that Cxt1p is involved in three important pathways: synthesis of GalXM, GXM, and glycosylinositol phosphorylceramides.

The *cxt1* Δ mutant is the first strain shown to have a specific defect in GalXM. This altered GalXM may be an important tool for studying the biological role of this polymer, especially in determining the importance of its xylose residues. In addition, the *cxt1* Δ strain has a partial defect in GXM xylosylation. GXM of other serotypes of *C. neoformans* is more heavily xylosylated than GXM of the serotype D strains studied here. It will be of further interest to assess the impact of *CXT1* deletion on those strains.

Although *cxt1* Δ cells grow normally *in vitro*, this strain has an attenuated ability to grow in the lungs of mice. This suggests that the xylose residues missing in the mutant are important for normal host-pathogen interactions. It has been previously shown that xylose is important for virulence, as a strain lacking UDP-xylose does not cause disease in mice, although it grows normally *in vitro* (33). That strain was mutated in UDP-glucuronic acid decarboxylase, an enzyme that is also present in mammals. The decarboxylase mutant is globally devoid of xylose, which would drastically alter capsule polysaccharides and glycolipids, and may also affect other glycoconjugates. In contrast, the *cxt1* Δ strain is altered in a fungal-specific enzyme (11) and has a much more restricted xylosylation defect, but still shows attenuated virulence. Together, these observations suggest that fungal-specific glycosyltransferases, such as Cxt1p, may be targets for selective and effective chemotherapeutic agents.

With these studies, we demonstrate for the first time a glycosyltransferase with a direct role in capsule production. This

discovery will enable us to address important questions such as the localization of this protein (and others with which it interacts), studies we are now pursuing. Furthermore, Cxt1p defines a new fungal-specific family of large glycosyltransferases (GT Family 90) (11). Other members of this group may also be involved in capsule synthesis, and future studies aimed at this protein family should increase our understanding of the biosynthesis of this fascinating structure.

Acknowledgments—We thank Morgann Reilly and Aki Yoneda for helpful discussions and comments on the manuscript, Indrani Bose for productive experimental suggestions, and Joe Heitman, June Kwon-Chung, Tom Kozel, and Gary Cox for strains and reagents. We also thank Hong Liu, Cara Griffith, and Matthew Williams for technical assistance and Parastoo Azadi and Christian Heiss at the Complex Carbohydrate Research Center (CCRC) in Athens, GA, for their efforts and advice on the structural analysis of GXM and GalXM.

REFERENCES

1. Chayakulkeeree, M., and Perfect, J. R. (2006) *Infect. Dis. Clin. N. Am.* **20**, 507–544, v–vi
2. Kwon-Chung, K. J., and Rhodes, J. C. (1986) *Infect. Immun.* **51**, 218–223
3. Bose, I., Reese, A. J., Ory, J. J., Janbon, G., and Doering, T. L. (2003) *Eukaryot. Cell* **2**, 655–663
4. Cherniak, R., Valafar, H., Morris, L. C., and Valafar, F. (1998) *Clin. Diagn. Lab. Immunol.* **5**, 146–159
5. Vaishnav, V. V., Bacon, B. E., O'Neill, M., and Cherniak, R. (1998) *Carbohydr. Res.* **306**, 315–330
6. McFadden, D. C., De Jesus, M., and Casadevall, A. (2006) *J. Biol. Chem.* **281**, 1868–1875
7. Janbon, G., Himmelreich, U., Moyrand, F., Improvisi, L., and Dromer, F. (2001) *Mol. Microbiol.* **42**, 453–467
8. Vecchiarelli, A. (2005) *Curr. Mol. Med.* **5**, 413–420
9. Pericolini, E., Cenci, E., Monari, C., De Jesus, M., Bistoni, F., Casadevall, A., and Vecchiarelli, A. (2006) *Cell. Microbiol.* **8**, 267–275
10. Moyrand, F., Fontaine, T., and Janbon, G. (2007) *Mol. Microbiol.* **64**, 771–781
11. Klutts, J. S., Levery, S. B., and Doering, T. L. (2007) *J. Biol. Chem.* **282**, 17890–17899
12. Nelson, R. T., Hua, J., Pryor, B., and Lodge, J. K. (2001) *Genetics* **157**, 935–947
13. McDade, H. C., and Cox, G. M. (2001) *Med. Mycol.* **39**, 151–154
14. Toffaletti, D. L., Rude, T. H., Johnston, S. A., Durack, D. T., and Perfect, J. R. (1993) *J. Bacteriol.* **175**, 1405–1411
15. Goins, C. L., Gerik, K. J., and Lodge, J. K. (2006) *Fungal Genet. Biol.* **43**, 531–544
16. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., Struhl, K., Albright, L. M., Coen, D. M., and Varki, A. (2004) in *Current Protocols in Molecular Biology* (Chanda, V. B., ed) pp. 2.9.1–2.9.15, John Wiley & Sons, New York
17. Yan, Z., Li, X., and Xu, J. (2002) *J. Clin. Microbiol.* **40**, 965–972
18. Pierini, L. M., and Doering, T. L. (2001) *Mol. Microbiol.* **41**, 105–115
19. Kozel, T. R., Levitz, S. M., Dromer, F., Gates, M. A., Thorkildson, P., and Janbon, G. (2003) *Infect. Immun.* **71**, 2868–2875
20. Sheng, S., and Cherniak, R. (1997) *Carbohydr. Res.* **301**, 33–40
21. Ashwell, G. (1957) *Methods Enzymol.* **3**, 73–105
22. York, W. S., Darvill, A. G., McNeill, M., Stevenson, T. T., and Albersheim, P. (1986) *Methods Enzymol.* **118**, 3–40
23. Ciucanu, I., and Kerek, F. (1984) *Carbohydr. Res.* **131**, 209–217
24. Griffith, C. L., Klutts, J. S., Zhang, L., Levery, S. B., and Doering, T. L. (2004) *J. Biol. Chem.* **279**, 51669–51676
25. Sommer, U., Liu, H., and Doering, T. L. (2003) *J. Biol. Chem.* **278**, 47724–47730
26. Klutts, J. S., Yoneda, A., Reilly, M. C., Bose, I., and Doering, T. L. (2006) *FEMS Yeast Res.* **6**, 499–512

C. neoformans β 1,2-Xylosyltransferase

27. Brandt, S., Thorkildson, P., and Kozel, T. R. (2003) *Clin. Diagn. Lab. Immunol.* **10**, 903–909
28. Eckert, T. F., and Kozel, T. R. (1987) *Infect. Immun.* **55**, 1895–1899
29. Spiropulu, C., Eppard, R. A., Otteson, E., and Kozel, T. R. (1989) *Infect. Immun.* **57**, 3240–3242
30. Gutierrez, A. L., Farage, L., Melo, M. N., Mohana-Borges, R. S., Guerardel, Y., Coddeville, B., Wieruszeski, J. M., Mendonca-Previato, L., and Previato, J. O. (2007) *Glycobiology* **17**, 1–11C
31. Heise, N., Gutierrez, A. L., Mattos, K. A., Jones, C., Wait, R., Previato, J. O., and Mendonca-Previato, L. (2002) *Glycobiology* **12**, 409–420
32. Owuor, E., Castle, S. A., Thompson, S. H., Garnsey, M. R., Klutts, J. S., Doering, T. L., and Levery, S. B. (2007) *Glycobiology* **17**, 1183
33. Moyrand, F., Klaproth, B., Himmelreich, U., Dromer, F., and Janbon, G. (2002) *Mol. Microbiol.* **45**, 837–849

